CA2902721C - Compounds and uses thereof for the modulation of hemoglobin - Google Patents

Compounds and uses thereof for the modulation of hemoglobin Download PDF

Info

Publication number
CA2902721C
CA2902721C CA2902721A CA2902721A CA2902721C CA 2902721 C CA2902721 C CA 2902721C CA 2902721 A CA2902721 A CA 2902721A CA 2902721 A CA2902721 A CA 2902721A CA 2902721 C CA2902721 C CA 2902721C
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
compound
ring
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2902721A
Other languages
English (en)
French (fr)
Other versions
CA2902721A1 (en
Inventor
Zhe Li
Qing Xu
Brian W. Metcalf
Stephen L. Ii Gwaltney
Jason R. Harris
Calvin W. YEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2902721(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/815,776 external-priority patent/US9458139B2/en
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of CA2902721A1 publication Critical patent/CA2902721A1/en
Application granted granted Critical
Publication of CA2902721C publication Critical patent/CA2902721C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2902721A 2013-03-15 2014-03-10 Compounds and uses thereof for the modulation of hemoglobin Active CA2902721C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/815,776 2013-03-15
US13/815,776 US9458139B2 (en) 2013-03-15 2013-03-15 Compounds and uses thereof for the modulation of hemoglobin
US201361905802P 2013-11-18 2013-11-18
US61/905,802 2013-11-18
PCT/US2014/022846 WO2014150289A1 (en) 2013-03-15 2014-03-10 Compounds and uses thereof for the modulation of hemoglobin

Publications (2)

Publication Number Publication Date
CA2902721A1 CA2902721A1 (en) 2014-09-25
CA2902721C true CA2902721C (en) 2021-09-14

Family

ID=51580734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902721A Active CA2902721C (en) 2013-03-15 2014-03-10 Compounds and uses thereof for the modulation of hemoglobin

Country Status (18)

Country Link
EP (1) EP2970315B1 (https=)
JP (2) JP6401772B2 (https=)
KR (1) KR20150132147A (https=)
CN (1) CN105209469A (https=)
AP (1) AP2015008720A0 (https=)
AU (1) AU2014237361A1 (https=)
BR (1) BR112015021980A2 (https=)
CA (1) CA2902721C (https=)
EA (1) EA201591427A1 (https=)
ES (1) ES2909634T3 (https=)
IL (1) IL240845A0 (https=)
MX (1) MX388013B (https=)
PE (1) PE20151907A1 (https=)
SG (1) SG11201507351PA (https=)
TW (1) TW201518286A (https=)
UY (1) UY35425A (https=)
WO (1) WO2014150289A1 (https=)
ZA (1) ZA201506390B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102142A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017218960A1 (en) 2016-06-17 2017-12-21 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
HRP20220295T1 (hr) * 2018-11-19 2022-05-13 Global Blood Therapeutics, Inc. Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin
AU2019387290A1 (en) 2018-11-29 2021-05-27 Pfizer Inc. Pyrazoles as modulators of hemoglobin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA818741B (en) * 1980-12-18 1983-07-27 Wellcome Found Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU668818B2 (en) * 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
JP2000514041A (ja) * 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
US6184228B1 (en) * 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
AUPQ105499A0 (en) * 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US20030022923A1 (en) * 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
EP2179987B1 (en) 2002-12-04 2013-02-13 Virginia Commonwealth University Use of heterocyclic carbaldehyde derivatives against sickle cell anemia
KR20060109979A (ko) * 2003-12-02 2006-10-23 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US20120122928A1 (en) * 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
WO2013102142A1 (en) * 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
EP3919056B1 (en) * 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin

Also Published As

Publication number Publication date
JP2018188481A (ja) 2018-11-29
EP2970315A4 (en) 2016-08-17
MX388013B (es) 2025-03-19
PE20151907A1 (es) 2016-01-20
CA2902721A1 (en) 2014-09-25
IL240845A0 (en) 2015-10-29
TW201518286A (zh) 2015-05-16
CN105209469A (zh) 2015-12-30
WO2014150289A1 (en) 2014-09-25
BR112015021980A2 (pt) 2017-07-18
AP2015008720A0 (en) 2015-09-30
EP2970315A1 (en) 2016-01-20
SG11201507351PA (en) 2015-10-29
JP6401772B2 (ja) 2018-10-10
ES2909634T3 (es) 2022-05-09
KR20150132147A (ko) 2015-11-25
AU2014237361A1 (en) 2015-09-17
JP2016512824A (ja) 2016-05-09
MX2015011509A (es) 2016-05-31
EP2970315B1 (en) 2021-09-15
ZA201506390B (en) 2017-03-29
EA201591427A1 (ru) 2016-01-29
UY35425A (es) 2014-10-31

Similar Documents

Publication Publication Date Title
CA2902721C (en) Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) Compounds and uses thereof for the modulation of hemoglobin
US10100040B2 (en) Compounds and uses thereof for the modulation of hemoglobin
US10858317B2 (en) Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US10450269B1 (en) Compounds and uses thereof for the modulation of hemoglobin
OA17478A (en) Compounds and uses thereof for the modulation of hemoglobin.
OA17480A (en) Compounds and uses thereof for the modulation of hemoglobin.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423